Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

• Status: Terminated
• Trial end date: 2015-04-01

Summary

RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin hydrochloride liposome together with vorinostat and bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and doxorubicin hydrochloride liposome in treating patients with relapsed or refractory multiple myeloma.

• Phase: Phase 1

Details

• Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
• Collaborators: Merck Sharp & Dohme Corp.; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI); Ortho Biotech, Inc.
• Treatments: Bortezomib; Doxorubicin; Liposomal doxorubicin; Vorinostat